Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

[Systemic mastocytosis. Underestimated condition in patients with idiopathic anaphylaxis].

Gülen T, Gottberg L, Dahlén B, Nilsson G, Hägglund H.

Lakartidningen. 2012 Feb 29-Mar 13;109(9-10):474-7. Review. Swedish. No abstract available.

PMID:
22530411
2.

Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?

Lange M, Żawrocki A, Nedoszytko B, Wasąg B, Niedoszytko M, Jassem E, Nowicki R, Żmijewski MA, Biernat W.

Int Arch Allergy Immunol. 2014;165(2):104-10. doi: 10.1159/000368799. Epub 2014 Nov 15.

PMID:
25402852
3.

Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.

Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, Mateo MB, Alonso Díaz de Durana MD, de la Hoz B, Del Pozo Gil MD, Caballero T, Rosado A, Sánchez Matas I, Teodósio C, Jara-Acevedo M, Mollejo M, García-Montero A, Orfao A, Escribano L.

J Allergy Clin Immunol. 2010 Jun;125(6):1269-1278.e2. doi: 10.1016/j.jaci.2010.02.019.

PMID:
20434205
4.

Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.

Kristensen T, Broesby-Olsen S, Vestergaard H, Bindslev-Jensen C, Møller MB; Mastocytosis Centre Odense University Hospital (MastOUH).

Eur J Haematol. 2012 Jul;89(1):42-6. doi: 10.1111/j.1600-0609.2012.01789.x. Epub 2012 Apr 28.

PMID:
22469616
5.

Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.

Noack F, Escribano L, Sotlar K, Nunez R, Schuetze K, Valent P, Horny HP.

Leuk Lymphoma. 2003 Feb;44(2):313-9.

PMID:
12688351
6.

Mastocytosis and related disorders.

Chiu A, Orazi A.

Semin Diagn Pathol. 2012 Feb;29(1):19-30. Review.

PMID:
22372203
7.

Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.

Pardanani A.

Am J Hematol. 2013 Jul;88(7):612-24. doi: 10.1002/ajh.23459. Epub 2013 May 30. Review.

8.

Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.

Perbellini O, Zamò A, Colarossi S, Zampieri F, Zoppi F, Bonadonna P, Schena D, Artuso A, Martinelli G, Chilosi M, Pizzolo G, Zanotti R.

Cytometry B Clin Cytom. 2011 Nov;80(6):362-8. doi: 10.1002/cyto.b.20606. Epub 2011 Jun 8.

9.

CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis.

Morgado JM, Perbellini O, Johnson RC, Teodósio C, Matito A, Álvarez-Twose I, Bonadonna P, Zamò A, Jara-Acevedo M, Mayado A, Garcia-Montero A, Mollejo M, George TI, Zanotti R, Orfao A, Escribano L, Sánchez-Muñoz L.

Histopathology. 2013 Dec;63(6):780-7. doi: 10.1111/his.12221. Epub 2013 Sep 20.

PMID:
24111625
10.

Mastocytosis: state of the art.

Horny HP, Sotlar K, Valent P.

Pathobiology. 2007;74(2):121-32. Review.

PMID:
17587883
11.

Immunophenotyping of mast cells: a sensitive and specific diagnostic tool for systemic mastocytosis.

van Daele PL, Beukenkamp BS, Geertsma-Kleinekoort WM, Valk PJ, van Laar JA, van Hagen PM, van der Velden VH.

Neth J Med. 2009 Apr;67(4):142-6.

12.

Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion.

Morgado JM, Sánchez-Muñoz L, Teodósio CG, Jara-Acevedo M, Alvarez-Twose I, Matito A, Fernández-Nuñez E, García-Montero A, Orfao A, Escribano L.

Mod Pathol. 2012 Apr;25(4):516-21. doi: 10.1038/modpathol.2011.192. Epub 2012 Jan 6.

13.

[IgE mediated anaphylaxis in a patient with systemic mastocytosis].

Escande H, Bennani I, Bulai Livideanu C, Uthurriague C, Paul C, Nougué J.

Ann Dermatol Venereol. 2013 Oct;140(10):641-4. doi: 10.1016/j.annder.2012.06.054. Epub 2013 Jun 24. French.

PMID:
24090896
14.

The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients.

Won D, Chi HS, Shim H, Jang S, Park CJ, Lee JH.

Leuk Res. 2013 Aug;37(8):883-8. doi: 10.1016/j.leukres.2013.04.020. Epub 2013 May 14.

PMID:
23683787
15.

Isolated flushes without permanent, fixed or other skin lesions in patients with systemic mastocytosis: a case series of 9 patients.

Lafont E, Lhermitte L, Damaj G, Soucie E, Barete S, Chandesris MO, Cabaret L, Guichard I, Durieu I, Retornaz F, Sarrot-Reynauld F, Hamidou M, Bruneau J, Aouba A, Dubreuil P, Lortholary O, Asnafi V, Hermine O, Georgin-Lavialle S.

Eur J Dermatol. 2015 Apr;25(2):182-4. doi: 10.1684/ejd.2014.2484. No abstract available.

PMID:
25547160
16.

Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.

Kibsgaard L, Skjold T, Deleuran M, Vestergaard C.

Acta Derm Venereol. 2014 May;94(3):363-4. doi: 10.2340/00015555-1687. No abstract available.

17.

Skin lesions and mast cells.

[No authors listed]

Blood. 2008 Jul 1;112(1):28. No abstract available.

18.

KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.

Broesby-Olsen S, Kristensen T, Vestergaard H, Brixen K, Møller MB, Bindslev-Jensen C; Mastocytosis Centre Odense University Hospital (MastOUH).

J Allergy Clin Immunol. 2013 Sep;132(3):723-8. doi: 10.1016/j.jaci.2013.02.019. Epub 2013 Apr 12.

PMID:
23587333
19.

Aggressive systemic mastocytosis mimicking sclerosing cholangitis.

Marbello L, Anghilieri M, Nosari A, Minola E, Cairoli R, Ricci F, Morra E.

Haematologica. 2004 Sep;89(9):ECR35.

20.

Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: a case review.

Ustun C, Savage NM, Gotlib J, Bhalla K, Manaloor E, George TI.

Am J Hematol. 2012 Feb;87(2):191-3. doi: 10.1002/ajh.22208. Epub 2011 Nov 12. No abstract available.

Supplemental Content

Support Center